Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
TheFly reported on January 20 that Piper Sandler raised its price target on CTMX to $10 from $6.50, keeping an Overweight rating. The firm noted that Initial Phase 1 data for varsetatug maseatecan in heavily pretreated metastatic colorectal cancer showed a 28% overall response rate, 94% disease control rate, and 5.8-month median PFS. This quarter, updated data with possible dose-dependent benefits from around 100 patients across three treatment cohorts are anticipated. Similarly, on the same day, Barclays analyst Etzer Darout also raised the price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $8 from $6 and maintained an Overweight rating. The imminent readout on colorectal cancer was mentioned by the firm as providing an attractive risk-reward profile. CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company that develops Probody therapeutics, condition-activated antibody prodrugs designed to improve cancer targeting and reduce off-tumor toxic
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics (NASDAQ:CTMX) had its price target raised by analysts at Cantor Fitzgerald from $6.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- CytomX Therapeutics to Present at Upcoming February Conferences [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at Upcoming February ConferencesGlobeNewswire
- CytomX Therapeutics (NASDAQ:CTMX) was given a new $10.00 price target on by analysts at Barclays PLC.MarketBeat
- CytomX Therapeutics (CTMX) Is Up 14.0% After Early Probody Colorectal Cancer Data Are Welcomed By Analysts – Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
CTMX
Earnings
- 11/6/25 - Miss
CTMX
Sec Filings
- 2/5/26 - Form SCHEDULE
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- CTMX's page on the SEC website